semaglutide alzheimer trial evoke and evoke+: design of two large‐scale, double‐blind, placebo‐controlled, phase 3 studies evaluating the neuroprotective effects of in early Alzheimer's disease - Atri - 2022 - Alzheimer's & Dementia New Alzheimer's Trial Reveals Surprising

Response heterogeneity is notable: some patients experience significant appetite suppression immediately, while others observe minimal change at this dose level

There is emerging evidence that GLP-1 receptor agonists may help reduce autoimmune inflammation, including in conditions like rheumatoid arthritis and lupus, although more studies are needed

Several RCTs showed the efficacy and tolerability of semaglutide for the treatment of obesity

Nanoscale 5 , 39313940 (2013)

The incorporation of a 104-week treatment period and 52-week extension, resulting in a total treatment period of 156 weeks in evoke/evoke+, allows for a comprehensive evaluation of the time to dementia progression in participants with baseline MCI, as well as long-term efficacy

Which GLP-1 drug fits my medical history